Eli Lilly launches phase 3 trial of oral cancer agent in non-Hodgkin's lymphoma

By Elaine Rigoli

Tampa, Fla., May 31 - Eli Lilly and Co. has started a phase 3 clinical trial studying enzastaurin, an investigational, multi-targeted, oral, cancer agent to treat patients with non-Hodgkin's lymphoma.

Lilly said enzastaurin will be evaluated as a maintenance therapy in patients with diffuse large B-cell lymphoma who have achieved remission following first-line therapy.

Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma, and the goal of maintenance therapy is to prevent relapse, the company said in a news release.

In March, Lilly announced the first phase 3 trial for enzastaurin in glioblastoma, a common type of brain cancer.

Indianapolis-based Eli Lilly is a global pharmaceutical corporation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.